Literature DB >> 33637772

GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study.

Patricio J Rodríguez-Valdés1, Matus Rehak2, Matias Iglicki3, Catharina Busch4, Dinah Zur5,6, Anna Sala-Puigdollers7, Samantha Fraser-Bell8, Marco Lupidi9, Jay Chhablani10,11, Zafer Cebeci12, Inês Laíns13,14, Voraporn Chaikitmongkol15, Adrian T Fung16,17, Mali Okada18, Jan Darius Unterlauft2, Lital Smadar5,6, Anat Loewenstein5,6,19.   

Abstract

To analyze functional and anatomical response patterns to dexamethasone (DEX) implant in diabetic macular edema (DME), to describe proportion of responders and non-responders, and to propose a new DME grading system. Retrospective, multicenter, observational cohort study. Naïve and non-naïve DME patients were treated with DEX, with visual acuity (VA) ≥ 0.2 logMAR and central subfield thickness (CST) of ≥ 300 µm. Functional and anatomical responses were graded after 2 and 4 months, and categorized as early and stable improvement, early and progressive improvement, pendular response, delayed improvement, and persistent non-response. 417 eyes were included (175 treatment naïve eyes). Compared to non-naïve eyes, naïve eyes showed a very good functional response (VA gain ≥ 10 letters) more frequently after 2 and 4 months (56% and 57% [naïve] vs. 33% and 28% [non-naïve], p < 0.001). A VA gain < 5 letters (non-response) after 2 and 4 months was seen in 18% and 16% of naïve eyes, and in 49% and 53% of non-naïve eyes (p < 0.001). A lack of anatomical response was rare in both groups, but more frequently in non-naïve eyes (12% vs. 4%, p = 0.003). Functionally and anatomically, naïve eyes showed most frequently an early and stable improvement (functionally: 77/175 44%; anatomically: 123/175 eyes, 70%). Most non-naïve eyes experienced no significant improvement functionally (97/242 eyes, 40%), despite a mostly early and stable improvement anatomical response pattern (102/242 eyes, 42%). Functional but not anatomical response patterns were influenced by baseline VA. Naïve and non-naïve eyes show different functional and anatomical response patterns to DEX implant. Functional non-responders are rare in naïve eyes, whereas anatomical non-response is unusual in both groups.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33637772      PMCID: PMC7910444          DOI: 10.1038/s41598-020-79288-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  20 in total

1.  Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.

Authors:  Raafay Sophie; Na Lu; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2015-04-11       Impact factor: 12.079

2.  Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.

Authors:  Emilia Maggio; Mauro Sartore; Marcella Attanasio; Giorgia Maraone; Massimo Guerriero; Antonio Polito; Grazia Pertile
Journal:  Am J Ophthalmol       Date:  2018-08-09       Impact factor: 5.258

3.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

4.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Authors:  David S Boyer; Young Hee Yoon; Rubens Belfort; Francesco Bandello; Raj K Maturi; Albert J Augustin; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup
Journal:  Ophthalmology       Date:  2014-06-04       Impact factor: 12.079

5.  OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.

Authors:  Dinah Zur; Matias Iglicki; Catharina Busch; Alessandro Invernizzi; Miriana Mariussi; Anat Loewenstein
Journal:  Ophthalmology       Date:  2017-09-19       Impact factor: 12.079

6.  Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.

Authors:  Neil M Bressler; Wesley T Beaulieu; Maureen G Maguire; Adam R Glassman; Kevin J Blinder; Susan B Bressler; Victor H Gonzalez; Lee M Jampol; Michele Melia; Jennifer K Sun; John A Wells
Journal:  Am J Ophthalmol       Date:  2018-08-02       Impact factor: 5.258

7.  DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study.

Authors:  Matias Iglicki; Catharina Busch; Dinah Zur; Mali Okada; Miriana Mariussi; Jay Kumar Chhablani; Zafer Cebeci; Samantha Fraser-Bell; Voraporn Chaikitmongkol; Aude Couturier; Ermete Giancipoli; Marco Lupidi; Patricio J Rodríguez-Valdés; Matus Rehak; Adrian Tien-Chin Fung; Michaella Goldstein; Anat Loewenstein
Journal:  Retina       Date:  2019-01       Impact factor: 4.256

8.  ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data.

Authors:  Pravin U Dugel; Joanna H Campbell; Szilárd Kiss; Anat Loewenstein; Vanessa Shih; Xiaoshu Xu; Nancy M Holekamp; Albert J Augustin; Allen C Ho; Victor H Gonzalez; Scott M Whitcup
Journal:  Retina       Date:  2019-01       Impact factor: 4.256

View more
  1 in total

1.  Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema.

Authors:  Ying-Ying Yu; Yong Cheng; Li-Bin Chang; Hui-Ka Xia; Xiao-Xin Li
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.